The company's stock price has surged by over 1,100% in the past 12 months, lifting its market value to over $16 billion. Summit stock jumped from about $12 on September 6 to a record high of $32 on September 13, but has retreated to around $23 since then. Spurred on by his son's death from brain cancer, Duggan started building a stake in Pharmacyclics, a maker of cancer drugs, in 2004. Pharmaceutical titan AbbVie bought the business for $21 billion in cash and stock in 2015, netting Duggan more than $3 billion, per Bloomberg. He joined Summit's board in 2019 and became CEO and chairman in 2020, making cancer drugs his principal focus.

---

Persons: —, Bob Duggan, Duggan, AbbVie Organizations: Service, Summit Therapeutics, Bloomberg, Business, Summit, UC Santa Barbara, Wall Street Journal, Computer, of Scientology, Duggan Investments Locations: Pharmacyclics